All In Biotech

Drug Trial Radar · NCT02526160

Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study With Open-Label Extension to Assess the Efficacy and Safety of KRN23 in Adults With X-linked Hypophosphatemia (XLH)

Last checked: Nov 20, 2026Latest source record: Jun 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 134 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

134

Actual

Start

Oct 22, 2015

Primary completion

Dec 22, 2016

Study completion Dec 6, 2018

Sponsor

Lead sponsor
Kyowa Kirin, Inc.Industry
Sponsor type
Industry
Collaborators
Kyowa Kirin Co., Ltd.
First posted
Aug 18, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary efficacy objective of this study is to establish the effect of burosumab treatment compared with placebo on increasing serum phosphorus levels in adults with XLH.

Conditions

  • X-linked Hypophosphatemia

Interventions

  • burosumabBiological

    solution for SC injection

  • PlaceboOther

    saline solution for SC injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving Mean Serum Phosphorus Levels Above the LLN (2.5 mg/dL [0.81 mmol/L]) at the Mid-Point of the Dose Interval, as Averaged Across Dose Cycles Between Baseline and Week 24Time frame: Baseline through Week 24

Locations

25 sites in 7 countries. Site status is shown where the registry gives one.

  • Children's Hospital of Los Angeles

    Los Angeles, California

  • University of California-San Francisco Medical Center

    San Francisco, California

  • Yale University School of Medicine

    New Haven, Connecticut

  • Indiana University Department of Medicine

    Indianapolis, Indiana

  • Johns Hopkins University

    Baltimore, Maryland

  • Duke University Medical Center

    Durham, North Carolina

  • The Ohio State University Wexner Medical Center

    Columbus, Ohio

  • Houston Methodist Hospital

    Houston, Texas

  • CHU de Bicêtre, Service d'Endocrinologie et des Maladies de la Reproduction

    Le Kremlin-Bicêtre, France

  • Hôpital Lariboisière, Dept. of Rheumatology

    Paris, France

  • CHU Paris Centre-Hôpital Cochin

    Paris, France

  • St. Vincent's University Hospital

    Dublin, Ireland

  • Azienda Ospedaliero Universitaria Careggi - Neurofarba

    Florence, Italy

  • Okayama Saiseikai General Hospital

    Okayama, Japan

  • Osaka City University Hospital

    Osaka, Japan

  • Osaka University Hospital

    Osaka, Japan

  • Toranomon Hospital

    Tokyo, Japan

  • The University of Tokyo Hospital

    Tokyo, Japan

  • Seoul National University Hospital

    Seoul, South Korea

  • Asan Medical Center

    Seoul, South Korea

  • University of Edinburgh Edinburgh Clinical Trials Unit (ECTU) - Western General Hospital

    Edinburgh, United Kingdom

  • Univeristy College of London Hospital

    London, United Kingdom

  • University of Oxford

    Oxford, United Kingdom

  • Northern General Hospital, Metabolic Bone Centre (Sorby Wing)

    Sheffield, United Kingdom

  • Royal National Orthopaedic Hospital

    Stanmore, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.